11.07.16
Evonik announced its third quarter and nine month results for2016
In the first nine months of this year, Evonik Group sales declined 8% year-on-year to €9,527 million. This was mainly due to lower selling prices. At the same time, volume sales rose by 2%. Adjusted EBITDA was 12% below the very high prior-year level at €1,728 million. The adjusted EBITDA margin was very good at 18.1%.
“In the third quarter of 2016 Evonik continued the volume growth seen in the first six months, despite the weak global economic conditions,” reported Klaus Engel, chairman of the Executive Board of Evonik Industries. “Based on this, we are confirming our outlook for the full year.”
Adjusted EBIT shrank by 18% to €1,191 million. Adjusted net income declined 19% to €501 million. Net income was €628 million, down 27% from the high prior-year level, which contained the proceeds from the divestment of the stake in Vivawest.
Evonik generated a clearly positive free cash flow of €488 million in the first nine months of 2016. This was partly due to a reduction in net working capital, while capital expenditures for property, plant and equipment were around the prior-year level at €589 million.
Evonik still expects sales for the full year to be slightly below the €13.5 billion reported in the previous year. Due to its strong market positions, balanced portfolio and concentration on high-growth businesses, the company assumes there will be continued high demand for its products and appreciable volume growth despite the difficult macro-economic conditions. The new production capacities taken into service in recent years and further intensification of sales activities are contributing to this. Selling prices are declining considerably, especially in the Nutrition & Care and Performance Materials segments, leading to the forecast slight reduction in sales.
Evonik is confirming the outlook for adjusted EBITDA specified at the end of the first six months: The company is confident that it can realize adjusted EBITDA in the upper half of the anticipated range of €2.0 billion to €2.2 billion.
The positive volume trend continued in the third quarter of 2016, with good demand for Evonik’s products worldwide. Selling prices declined further, partly because lower raw material prices were passed on to customers. The Group posted a drop of 6% in sales to €3,164 million. Adjusted EBITDA was €578 million, 11% lower than in the exceptionally strong prior-year quarter. The adjusted EBITDA margin was very good at 18.3 percent. Adjusted EBIT declined 16% to €396 million. Adjusted net income declined 17% to €247 million. Net income increased 19% to €223 million as a result of the reduced impact of one-off factors.
In September 2016 Evonik successfully placed bonds with a nominal value of €1.9 billion and an average interest rate of 0.35% on the capital market via its subsidiary Evonik Finance B.V. The proceeds will be used to finance the planned acquisition of Air Products’ specialty and coating additives business. The responsible antitrust authorities in the USA, Germany and most European countries have already approved the transaction, which is expected to be closed by the end of the year.
In the Performance Materials segment, sales dropped 7% to €797 million in the third quarter of 2016. The main reason was the reduction in selling prices as lower raw material costs were passed on to customers. By contrast, volumes rose considerably thanks to good demand. Adjusted EBITDA grew 11% to €104 million. This was primarily due to a rise in volumes, high capacity utilization at production facilities, and the initial effects of cost-cutting measures. The adjusted EBITDA margin was 13.0 percent, up from 11.0% in the third quarter of 2015. In the first nine months of the year, sales in the Performance Materials segment shrank 9% to €2,399 million. With volumes up, the decline was caused by the oil-driven drop in selling prices. Adjusted EBITDA improved 11% to €273 million and the adjusted EBITDA margin rose to 11.4 percent.
In the first nine months of this year, Evonik Group sales declined 8% year-on-year to €9,527 million. This was mainly due to lower selling prices. At the same time, volume sales rose by 2%. Adjusted EBITDA was 12% below the very high prior-year level at €1,728 million. The adjusted EBITDA margin was very good at 18.1%.
“In the third quarter of 2016 Evonik continued the volume growth seen in the first six months, despite the weak global economic conditions,” reported Klaus Engel, chairman of the Executive Board of Evonik Industries. “Based on this, we are confirming our outlook for the full year.”
Adjusted EBIT shrank by 18% to €1,191 million. Adjusted net income declined 19% to €501 million. Net income was €628 million, down 27% from the high prior-year level, which contained the proceeds from the divestment of the stake in Vivawest.
Evonik generated a clearly positive free cash flow of €488 million in the first nine months of 2016. This was partly due to a reduction in net working capital, while capital expenditures for property, plant and equipment were around the prior-year level at €589 million.
Evonik still expects sales for the full year to be slightly below the €13.5 billion reported in the previous year. Due to its strong market positions, balanced portfolio and concentration on high-growth businesses, the company assumes there will be continued high demand for its products and appreciable volume growth despite the difficult macro-economic conditions. The new production capacities taken into service in recent years and further intensification of sales activities are contributing to this. Selling prices are declining considerably, especially in the Nutrition & Care and Performance Materials segments, leading to the forecast slight reduction in sales.
Evonik is confirming the outlook for adjusted EBITDA specified at the end of the first six months: The company is confident that it can realize adjusted EBITDA in the upper half of the anticipated range of €2.0 billion to €2.2 billion.
The positive volume trend continued in the third quarter of 2016, with good demand for Evonik’s products worldwide. Selling prices declined further, partly because lower raw material prices were passed on to customers. The Group posted a drop of 6% in sales to €3,164 million. Adjusted EBITDA was €578 million, 11% lower than in the exceptionally strong prior-year quarter. The adjusted EBITDA margin was very good at 18.3 percent. Adjusted EBIT declined 16% to €396 million. Adjusted net income declined 17% to €247 million. Net income increased 19% to €223 million as a result of the reduced impact of one-off factors.
In September 2016 Evonik successfully placed bonds with a nominal value of €1.9 billion and an average interest rate of 0.35% on the capital market via its subsidiary Evonik Finance B.V. The proceeds will be used to finance the planned acquisition of Air Products’ specialty and coating additives business. The responsible antitrust authorities in the USA, Germany and most European countries have already approved the transaction, which is expected to be closed by the end of the year.
In the Performance Materials segment, sales dropped 7% to €797 million in the third quarter of 2016. The main reason was the reduction in selling prices as lower raw material costs were passed on to customers. By contrast, volumes rose considerably thanks to good demand. Adjusted EBITDA grew 11% to €104 million. This was primarily due to a rise in volumes, high capacity utilization at production facilities, and the initial effects of cost-cutting measures. The adjusted EBITDA margin was 13.0 percent, up from 11.0% in the third quarter of 2015. In the first nine months of the year, sales in the Performance Materials segment shrank 9% to €2,399 million. With volumes up, the decline was caused by the oil-driven drop in selling prices. Adjusted EBITDA improved 11% to €273 million and the adjusted EBITDA margin rose to 11.4 percent.